GoAI
Get started
Adicet Bio, Inc. logo

Adicet Bio, Inc.

ACET

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$9.19

−$0.19 · -2.03%

Aug 21, 4:00 PM ET

ACET company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

31

Expensive

Momentum

47

Neutral

Sentiment

58

Mixed

Risk resilience

23

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Chen Schor
Listed since
Jan 26, 2018
Employees
102

Market position

Day range

Current $9.19

52-week range

Current $9.19

Open
$9.42
Previous close
$9.38
Volume
80.5K
0.82× average
Average volume
97.99K
Average daily volume
Market cap
85.91M USD
Beta
1.59
Market reference 1
50-day average
$8.4934
+8.20% above average
200-day average
$8.1421
+12.87% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
33.85M USD
P/E (TTM)
-0.8×
P/B (TTM)
0.82×
P/S (TTM)
0×
EV / EBITDA
-0.31×
Earnings yield
-201.30%
Free cash flow yield
-167.14%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-73.36%
Return on assets
-60.72%
Return on invested capital
-70.18%

Financial health

Debt / equity
0.11×
Current ratio
7.47×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends174%-121%-416%-711%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Operating margin, FY2021: -631.38%Operating margin, FY2022: -290.32%Net margin, FY2021: -637.19%Net margin, FY2022: -279.27%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Operating margin FY2021 -631.38%. Operating margin FY2022 -290.32%. Net margin FY2021 -637.19%. Net margin FY2022 -279.27%.

Income trends

Revenue

24.99M USD+156.83%

Operating income

−122.11M USD+4.31%

Net income

−116.8M USD+0.27%
Income trends across reported periods42.69M USD−28.12M USD−98.93M USD−169.74M USDRevenue, FY2021: 9.73M USDRevenue, FY2022: 24.99M USDOperating income, FY2021: −61.43M USDOperating income, FY2022: −72.55M USDOperating income, FY2023: −152.04M USDOperating income, FY2024: −127.62M USDOperating income, FY2025: −122.11M USDNet income, FY2021: −62M USDNet income, FY2022: −69.79M USDNet income, FY2023: −142.66M USDNet income, FY2024: −117.12M USDNet income, FY2025: −116.8M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 9.73M USD. Revenue FY2022 24.99M USD. Operating income FY2021 −61.43M USD. Operating income FY2022 −72.55M USD. Operating income FY2023 −152.04M USD. Operating income FY2024 −127.62M USD. Operating income FY2025 −122.11M USD. Net income FY2021 −62M USD. Net income FY2022 −69.79M USD. Net income FY2023 −142.66M USD. Net income FY2024 −117.12M USD. Net income FY2025 −116.8M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue———24.99M USD9.73M USD
Cost of goods sold6.38M USD————
Gross profit−6.38M USD——24.99M USD9.73M USD
Research and development99.13M USD99.32M USD106.04M USD71.25M USD48.94M USD
Selling, general, and administrative22.99M USD28.29M USD26.53M USD26.3M USD22.22M USD
Operating expenses115.73M USD127.62M USD152.04M USD97.54M USD71.16M USD
Interest income5.78M USD10.71M USD9.98M USD3.76M USD91K USD
Interest expense36K USD4K USD25K USD80K USD176K USD
Depreciation and amortization6.38M USD6.47M USD6.1M USD5.01M USD1.54M USD
Operating income−122.11M USD−127.62M USD−152.04M USD−72.55M USD−61.43M USD
Net income−116.8M USD−117.12M USD−142.66M USD−69.79M USD−62M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
-240.77%
11 comparable reports
Latest EPS result
-1.99
Estimate -1.69 · Miss by 17.75%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.31-2.15-4-5.85Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 6, 2025: actual -5.12, estimate -0.36, surprise -1322.22%, Miss. Q2 2025, reported May 6, 2025: actual -4.96, estimate -5.31, surprise +6.53%, Beat. Q3 2025, reported Aug 7, 2025: actual -5.44, estimate -4.86, surprise -11.89%, Miss. Q4 2025, reported Nov 5, 2025: actual -4.64, estimate -4.16, surprise -11.54%, Miss. Q1 2026, reported Mar 12, 2026: actual -2.94, estimate -2.99, surprise +1.59%, Beat. Q2 2026, reported May 13, 2026: actual -1.88, estimate -2.93, surprise +35.84%, Beat. Q3 2026, reported Aug 5, 2026: actual -1.99, estimate -1.69, surprise -17.75%, Miss. Q4 2026, reported Nov 4, 2026: actual —, estimate -1.39, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates3.04M2.2M1.37M531.25KQ1 '24EstimateQ3 '24EstimateQ4 '24EstimateQ1 '25EstimateQ1 '26Estimate
Q1 2024, reported Mar 19, 2024: actual —, estimate 625K USD, surprise —, Comparison unavailable. Q3 2024, reported Aug 13, 2024: actual —, estimate 625K USD, surprise —, Comparison unavailable. Q4 2024, reported Nov 6, 2024: actual —, estimate 625K USD, surprise —, Comparison unavailable. Q1 2025, reported Mar 6, 2025: actual —, estimate 625K USD, surprise —, Comparison unavailable. Q1 2026, reported Mar 12, 2026: actual —, estimate 2.86M USD, surprise —, Comparison unavailable.

ACET news

zacks.com

Are Medical Stocks Lagging Adicet Bio (ACET) This Year?

Here is how Adicet Bio, Inc. (ACET) and Agilent Technologies (A) have performed compared to their sector so far this year.

Read source
seekingalpha.com

Adicet Bio: A Cheap Gamma Delta T-Cell Play

Adicet Bio offers a differentiated allogeneic gamma delta CAR-T platform targeting autoimmune diseases, trading below cash value with a pivotal readout imminent. Early prula-cel data in lupus nephritis showed 50%…

Read source
zacks.com

Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet

The consensus price target hints at a 301.6% upside potential for Adicet Bio (ACET). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could…

Read source
marketbeat.com

Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy

Adicet Bio NASDAQ: ACET expects to report clinical data this quarter for its lead autoimmune program, ADI-001, also known as prula-cel, including results in lupus nephritis (LN) and systemic lupus erythematosus (SLE),…

Read source
zacks.com

All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy

Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read source
businesswire.com

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today…

Read source

ACET peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ACET

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
2.22M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
901.09K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
227.48K
Weight
0.02%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
136.2K
Weight
0.00%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
133.8K
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%
Avantis U.S. Small Cap Equity ETF logoAvantis U.S. Small Cap Equity ETFAVSC
Market value
52.78K
Weight
—
AUM
3.16B USD
Expense ratio
0.25%
Price / 1D
$73.84+0.70%

Continue in GoAI

Research ACET

research.disclaimer